Journal
CANCER LETTERS
Volume 227, Issue 1, Pages 1-7Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2004.11.006
Keywords
BRCA1; breast cancer; DNA damage; ubiquitination; BRCT domain
Categories
Funding
- NCI NIH HHS [CA92309] Funding Source: Medline
Ask authors/readers for more resources
Women carrying one mutated BRCA1 allele are at increased risk of developing breast and ovarian cancer but tumor initiation requires the loss of the wild-type allele indicating that it is a tumor suppressor gene. In the 10 years since the cloning of BRCA1, a function for the gene product in the DNA damage response has been established. However, identifying the exact biochemical activities of BRCA1 has been a more difficult task. Our current understanding suggests that the molecular functions mediated by the terminal ends of BRCA1, which include an E3 ubiquitin ligase activity at the N-terminus and a protein-protein interaction surface at the C-terminus, are critical to the function of this protein in the response to DNA damage. (C) 2004 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available